Menu
Menu
Imagine a therapy session where your client brings up an interest in using psychedelics as part of their healing journey; after all, the options are getting plenty of mainstream attention. Are you prepared to guide them through the maze of information, potential benefits, and risks? This workshop addresses the increasing curiosity about psychedelic-assisted therapy and equips you with the knowledge and tools to respond effectively. You’ll review cutting-edge research of psychedelic compounds like MDMA and psilocybin, illustrating how these substances are reshaping treatment approaches for addiction and trauma. You’ll also explore practical ways to translate groundbreaking research into meaningful clinical practice, ensuring your clients receive informed, balanced, and ethical guidance. You’ll discover:
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 2 hours CPD for points calculation by your association.
Elizabeth Nielson, PhD, is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.
Speaker Disclosures:
Access never expires for this product.
For a more detailed outline that includes times or durations of time, if needed, please contact cepesi@pesi.com
Understanding the Basics of Psychedelic Compounds
II. Clinical Trials and Future Implications
III. Practical Techniques for Integration into Clinical Practice
IV. Engaging Clients and Ethical Considerations
Please wait ...